- CohBar Stock Doubles: Company Agrees to Merge With Morphogenesis To Advance Late-Stage Oncology Candidates (May 23, 2023)
- CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy (May 23, 2023)
- M2GEN Rebrands to Aster Insights (April 14, 2023)
- Moffitt Cancer Center and Deerfield Management Launch Bayfield Therapeutics (September 19, 2022)
- Turnstone Biologics and Moffitt Cancer Center Announce Strategic Alliance to Advance Next-Generation TIL Therapies for Solid Tumors (July 6, 2022)
- Sterotherapeutics Signs Licensing Agreement Aimed to Improve the Treatment of Multiple Myeloma (March 30, 2022)
- Turnstone Biologics Announces Research Collaboration with Moffitt Cancer Center to Advance Novel TIL Immunotherapies for Solid Tumor Indications (November 29, 2021)
- Quantiphi Partners with Moffitt Cancer Center to Leverage Machine Learning for Improved Accuracy and Throughput of Cell Taxonomy in Hematologic Malignancies (November 16, 2021)
- Memgen Announces FDA Clearance of IND Application for MEM-288 (November 3, 2021)
- Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day (July 20, 2021)
- EXUMA Biotech Announces Collaboration with Moffitt Cancer Center for the Development of a Rapid-Point-Of-Care SC CAR-T Program (January 11, 2021)
- Indee Labs Announces Successful Early Access Program Launch (January 5, 2021)
- APIS Assay Technologies Ltd. and Moffitt Cancer Center sign Master Collaboration Agreement on TROLL Biomarker assessment ( December 9, 2020)
- Precigen Announces Dosing of First Patients with UltraCAR-T® Cells Manufactured Using Proprietary UltraPorator™ System in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials (November 16, 2020)
- Memgen Announces Exclusive License Agreements With Moffitt Cancer Center to Develop Innovative Cancer Immunotherapies (April 21,2020)
- DeMelle OncoPharma Licenses Clinical-Stage Technology from Moffitt Cancer Center for New Targeted Pancreatic Cancer Treatment (March 4, 2020)
- Krystyna Kowalczyk Named CEO of Moffitt Cancer Center’s Immunotherapy Contract Research Organization (January 28, 2020)
- ANP Technologies, in Partnership with Fulgent Pharma, Teams with Moffitt Cancer Center to Develop a New Class of Leukemia Therapies (January 10, 2020)
- ThreatWarrior and Moffitt Cancer Center work together to bring Next-Generation Cybersecurity to the Health Care Industry (October 7, 2019)
- Moffitt Cancer Center Launches Immunotherapy Contract Research Organization (October 3, 2019)
- Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS) (June 26, 2019)
- Moffitt Cancer Center Partners with TuHURA Biopharma Inc. to Develop a New Generation of Targeted Immunotherapies (Business Insider, May 29, 2019)
- Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome (Global News Wire, August 21, 2018)
- Moffitt Cancer Center Announces Licensing Agreement to Develop New Therapeutic Cancer Vaccine (July 10, 2018)
- Licensing, partnerships drive Moffitt financial gains (Tampa Bay Business Journal May 18, 2018)
- GLG Pharma, a Moffitt Start-up, Announces a Joint Strategic Partnership with Skyline Medical and Helomics (November 28, 2017)
- Moffitt Start-up Wins Biopitch Competition at BioFlorida Conference (November 1, 2017)
- Moffitt Cancer Center Founder H. Lee Moffitt Receives BioFlorida Lifetime Achievement Award (October 12, 2017)
- Hearst invests in Moffitt Cancer Center subsidiary M2Gen (September 20, 2017)Moffitt Cancer Center & Cvergenx Partner to Personalize Radiation Therapy (August 9, 2017)
- Lion Biotechnologies Announces New Sponsored Research and Clinical Grant Agreements with H. Lee Moffitt Cancer Center and Research Institute (December 20, 2016)
- Innovation Office Connects Moffitt and Signal Genetics for Myeloma Research Incyte and Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance (June 1, 2016)
- Moffitt Cancer Center Showcases Startups at 10th Annual Business of Biotech Conference(February 18, 2016)
- Top research taking place in Tampa leads to national recognition for innovation, patents (83 Degrees, December 15, 2015)
- Dr. Letson of Moffitt Cancer Center named Fellow of the National Academy of Inventors(December 16, 2015)
- Moffitt Cancer Center and Ignyta, Inc. Enter into Cancer Research Collaboration for RXDX-106(November 20, 2015)
- Moffitt Cancer Center Grants Aptose Exclusive Global Rights to Highly Potent Multi-Targeting Epigenetic Inhibitors (November 11, 2015)
- HealthMyne, Inc. and Moffitt Cancer Center Sign Imaging Analytics Technology Agreement (Business Wire, October 6, 2015)
- Bristol-Myers Squibb and Moffitt Cancer Center Enter into a Collaboration Agreement (Business Wire, September 25, 2015)
- Signal Genetics and Moffitt Cancer Center Enter Into Sponsored Research Agreement in Multiple Myeloma (September 8, 2015)
- Rosetta Genomics Announces Selection of First Pilot Project Grant under Strategic Alliance with Moffitt Cancer Center (May 26, 2015)
- Prescient Therapeutics Acquires Exclusive Worldwide License for Cancer Biomarker p27(Prescient Therapeutics, February 9, 2015)
- Celgene Wins Rights To Moffitt's Investigational MDS Therapy (BioProcess Online, November 20, 2014)
- Moffitt signs deal for experimental treatment (Business Observer, November 18, 2014)
- Moffitt, Celgene pair on treatment for cancer that struck GMA host Robin Roberts (Tampa Bay Business Journal, November 17, 2014)
- Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases (Business Wire, November 17, 2014)
- HealthMyne Put the Band Back Together to Unite Medical Images & Data (Xconomy, November 11, 2014)
- Forma Therapeutics and Moffitt Cancer Center Establish Multiyear Epigenetics Alliance (Business Wire, September 23, 2014)
- Rosetta Genomics and Moffitt Cancer Center Enter into Strategic Alliance to Develop microRNA-based Cancer Diagnostics (September 2, 2014)
- Virax Holdings Ltd enters in to option agreement to acquire Worldwide License from Moffitt Cancer Center (Reuters, Sunday, 4 May 2014 )
Call Today
